Seres Therapeutics Stock Beta
| MCRB Stock | USD 0.77 0.04 5.48% |
Seres Therapeutics fundamentals help investors to digest information that contributes to Seres Therapeutics' financial success or failures. It also enables traders to predict the movement of Seres Stock. The fundamental analysis module provides a way to measure Seres Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seres Therapeutics stock.
Seres | Beta |
Seres Therapeutics Company Beta Analysis
Seres Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Seres Therapeutics Beta | 2.05 |
Most of Seres Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seres Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Seres Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Seres Therapeutics is extremely important. It helps to project a fair market value of Seres Stock properly, considering its historical fundamentals such as Beta. Since Seres Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Seres Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Seres Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Seres Therapeutics has a Beta of 2.05. This is 138.37% higher than that of the Biotechnology sector and 47.48% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Seres Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seres Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Seres Therapeutics could also be used in its relative valuation, which is a method of valuing Seres Therapeutics by comparing valuation metrics of similar companies.Seres Therapeutics is currently under evaluation in beta category among its peers.
Seres Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Seres Therapeutics from analyzing Seres Therapeutics' financial statements. These drivers represent accounts that assess Seres Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Seres Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 410.2M | 184.2M | 763.9M | 605.2M | 179.2M | 170.2M | |
| Enterprise Value | 383.1M | 105.6M | 633.1M | 604.8M | 265.2M | 251.9M |
Seres Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Seres Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Seres Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Seres Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 342.2 K | Lion Point Capital, Lp | 2024-09-30 | 340.8 K | State Street Corp | 2024-06-30 | 339.5 K | Verition Fund Managegment, Llc | 2024-06-30 | 314.2 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 267.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 250 K | Citigroup Inc | 2024-09-30 | 218.2 K | Northern Trust Corp | 2024-09-30 | 218.2 K | Ubs Group Ag | 2024-06-30 | 200.7 K | Flagship Ventures Management, Inc. | 2024-06-30 | 23.1 M | Fmr Inc | 2024-09-30 | 22.9 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Seres Therapeutics will likely underperform.
Seres Fundamentals
| Return On Equity | -15.56 | ||||
| Return On Asset | -0.097 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 158.02 M | ||||
| Shares Outstanding | 170.74 M | ||||
| Shares Owned By Insiders | 13.19 % | ||||
| Shares Owned By Institutions | 37.56 % | ||||
| Number Of Shares Shorted | 17.85 M | ||||
| Price To Earning | (4.04) X | ||||
| Price To Book | 5.49 X | ||||
| Price To Sales | 1.04 X | ||||
| Revenue | 126.33 M | ||||
| Gross Profit | (165.79 M) | ||||
| EBITDA | (85.43 M) | ||||
| Net Income | (113.72 M) | ||||
| Cash And Equivalents | 195.8 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 213.94 M | ||||
| Debt To Equity | 3.35 % | ||||
| Current Ratio | 2.35 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (117.35 M) | ||||
| Short Ratio | 5.75 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Price To Earnings To Growth | (0.11) X | ||||
| Target Price | 3.87 | ||||
| Number Of Employees | 233 | ||||
| Beta | 2.05 | ||||
| Market Capitalization | 131.23 M | ||||
| Total Asset | 358.6 M | ||||
| Retained Earnings | (978.24 M) | ||||
| Working Capital | 76.75 M | ||||
| Current Asset | 207.61 M | ||||
| Current Liabilities | 10.92 M | ||||
| Net Asset | 358.6 M |
About Seres Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seres Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seres Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seres Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Seres Therapeutics Piotroski F Score and Seres Therapeutics Altman Z Score analysis. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.